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Abstract
Background: Mutations in Parkin are the most common cause of autosomal recessive Parkinson disease (PD). The
mitochondrially localized E3 ubiquitin-protein ligase Parkin has been reported to be involved in respiratory chain function
and mitochondrial dynamics. More recent publications also described a link between Parkin and mitophagy.
Methodology/Principal Findings: In this study, we investigated the impact of Parkin mutations on mitochondrial function
and morphology in a human cellular model. Fibroblasts were obtained from three members of an Italian PD family with two
mutations in Parkin (homozygous c.1072delT, homozygous delEx7, compound-heterozygous c.1072delT/delEx7), as well as
from two relatives without mutations. Furthermore, three unrelated compound-heterozygous patients (delEx3-4/duplEx7-
12, delEx4/c.924C.T and delEx1/c.924C.T) and three unrelated age-matched controls were included. Fibroblasts were
cultured under basal or paraquat-induced oxidative stress conditions. ATP synthesis rates and cellular levels were detected
luminometrically. Activities of complexes I-IV and citrate synthase were measured spectrophotometrically in mitochondrial
preparations or cell lysates. The mitochondrial membrane potential was measured with 5,59,6,69-tetrachloro-1,19,3,39-
tetraethylbenzimidazolylcarbocyanine iodide. Oxidative stress levels were investigated with the OxyBlot technique. The
mitochondrial network was investigated immunocytochemically and the degree of branching was determined with image
processing methods. We observed a decrease in the production and overall concentration of ATP coinciding with increased
mitochondrial mass in Parkin-mutant fibroblasts. After an oxidative insult, the membrane potential decreased in patient
cells but not in controls. We further determined higher levels of oxidized proteins in the mutants both under basal and
stress conditions. The degree of mitochondrial network branching was comparable in mutants and controls under basal
conditions and decreased to a similar extent under paraquat-induced stress.
Conclusions: Our results indicate that Parkin mutations cause abnormal mitochondrial function and morphology in non-
neuronal human cells.
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Introduction
Mutations in the Parkin gene (MIM 602544) are the most
common known cause of early-onset Parkinson disease (PD; MIM
168600), accounting for up to 77% of the cases with an age of
onset ,30 years [1]. Parkin encodes a 465-amino-acid protein with
a modular structure [2,3].
In addition to Parkin’s roles as E3 ligase and neuroprotectant, it
has been reported to be involved in mitochondrial function [4]. This
connection was first established when Parkin loss-of-function mice
presented with reduced expression of mitochondrial function- and
oxidative stress-related proteins, decreased mitochondrial respira-
tory capacity and increased oxidative damage [5]. Similar results
were obtained in additional animal models [6,7,8,9].
Investigation of mitochondrial function in human samples
supports the findings from animal studies. Functional assays in
leukocytes as well as fibroblasts of patients with homozygous or
compound-heterozygous Parkin mutations consistently showed
PLoS ONE | www.plosone.org 1 September 2010 | Volume 5 | Issue 9 | e12962
reduced mitochondrial complex I activity, coinciding with reduced
ATP synthesis rates [10,11].
Another intriguing finding is that Parkin is involved in the
regulation of mitochondrial morphology. The knockdown of Parkin
causes swollen mitochondria in Drosophila indirect flight muscles
[12,13]. As a human model, fibroblasts from PD patients with
Parkin mutation have been used to investigate mitochondrial
morphology and revealed a greater degree of mitochondrial
branching in the patients than in controls [11].
Recently, several publications linked Parkin and mitophagy in
different cellular models [14,15,16,17]. Induced by loss of
mitochondrial membrane potential, Parkin is recruited by the
PTEN-induced putative kinase 1 (PINK1; MIM 608309) to
dysfunctional mitochondria, where it mediates their engulfment by
autophagosomes and their selective elimination [14,17,18,19]. In
Drosophila, terminally damaged mitochondria are labeled for
degradation by ubiquitylation of mitofusion (mfn) [20,21,22].
Most of the above-mentioned data explaining Parkin’s function
with respect to PD were either obtained in animal models or in
small sets of human cellular samples. Here, we evaluated a larger
sample of Parkin-mutant fibroblasts for changes in mitochondrial
function and morphology.
Materials and Methods
Ethics statement
The study was approved by the ethics committee of the University
of Lu¨beck and all participants gave written, informed consent.
Patients
Skin biopsies were obtained from 11 individuals including six
affected cases (mean age 6 STD: 56.2613.3 years) with two
mutant Parkin alleles and five age-matched controls (mean
age6STD: 51.8611.5 years) without mutations in known PD
genes. Phenotypic and genotypic data are summarized in Table 1
(further clinical details were published earlier [23]).
Tissue culture
Fibroblasts were cultured in high glucose Dulbecco’s Modified
Eagle’s Medium supplemented with 10% foetal bovine serum and
1% penicillin–streptomycin (all PAA, Pasching, Austria) at 37uC, 5%
CO2. In all assays, fibroblast passage numbers were matched (,15).
To induce oxidative stress, cells were treated with 2 mM
paraquat for 24 h (Sigma-Aldrich, St. Louis, MO).
Assessment of mitochondrial function
Cellular ATP synthesis rates were determined according to a
published protocol [24]. In brief, the amount of protein was
determined using the Dc Protein Assay Kit (Bio-Rad, Hercules,
CA, USA) following the manufacturer’s instructions. Fibroblasts
were harvested and diluted with cell suspension buffer (150 mmol/
l KCl, 25 mmol/l Tris-HCl; pH 7.6, 2 mmol/l EDTA pH 7.4, 10
mmol/l KPO4 pH 7.4, 0.1 mmol/l MgCl2 and 0.1% [w/v] BSA)
to a concentration of 1 mg protein per ml. ATP synthesis was
initiated by the addition of 250 ml of the cell suspension to 750 ml
of substrate buffer (10 mmol/l malate, 10 mmol/l pyruvate, 1
mmol/l ADP, 40 mg/ml digitonin and 0.15 mmol/l adenosine
pentaphosphate). Cells were incubated at 37uC for 10 min. At 0
and 10 min, 50 ml aliquots of the reaction mixture were
withdrawn, quenched in 450 ml of boiling 100 mmol/l Tris-HCl,
4 mmol/l EDTA pH 7.75 for 2 min and further diluted 1/10 in
the quenching buffer. The quantity of ATP was measured in a
luminometer (Berthold, Detection Systems, Pforzheim, Germany)
with the ATP Bioluminescence Assay Kit (Roche Diagnostics,
Basel, Switzerland) following the manufacturer’s instructions.
Cellular ATP levels were quantified in intact cells as described
[25]. In both assays, the control average value per run was set to
100% and the relative average patient value was calculated. By
this, variation of absolute ATP levels between experimental runs
due to variable quality of the used kit was not taken into account.
To investigate respiratory chain function, mitochondria were
isolated as published [25]. Mitochondrial respiratory chain
complex activities were measured spectrophotometrically and
expressed as ratios of citrate synthase activity [25].
The mitochondrial membrane potential was analyzed using
5,59,6,69-tetrachloro-1,19,3,39-tetraethylbenzimidazolylcarbocya-
nine iodide (Invitrogen, Carlsbad, CA) [25].
All measurements were performed in duplicate and in at least
three independent runs per sample on a microplate reader
(Synergy HT, BioTek, Winooski, VT).
Table 1. Genotypic and phenotypic characterisation of investigated individuals.
Code Sex
Age of onset
(yr) Age (yr) Mutation Zygosity Clinical status
Mutants B11 M 64 79 delEx7+c.1072delT compound heterozygous affected
B125 M 43 62 c.1072delT homozygous affected
B300 F 34 49 delEx7 homozygous affected
L3035 M 31 49 delEx3-4+duplEx7-12 compound heterozygous affected
L3048 M 15 57 delEx4+c.924C.T compound heterozygous affected
L3244 F 37 41 delEx1+c.924C.T compound heterozygous affected
Ø 6 STD 37.3616.1 56.2613.3
Controls 802.1 F n/a 60 none n/a unaffected
902.1 F n/a 68 none n/a unaffected
B963 M n/a 44 none n/a unaffected
B964 M n/a 44 none n/a unaffected
L3293 M n/a 43 none n/a unaffected
Ø 6 STD 51.8611.5
doi:10.1371/journal.pone.0012962.t001
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Quantification of oxidized proteins
Protein carbonyl levels were measured with the OxyBlot kit
(Millipore, Billerica, MA), according to the manufacturer’s
recommendations. Carbonyl groups in the protein side chains
were derivatized to 2, 4-dinitrophenylhydrazine (DNP). Western
blot analysis was performed with an antibody against DNP. Equal
loading was assessed using an antibody against mouse polyclonal
anti-b-actin (Sigma-Aldrich, St. Louis, MO). The experiment was
performed three times and a representative blot was analyzed
densitometrically with TotalLab software (Nonlinear Dynamics,
Newcastle, UK).
Assessment of mitochondrial branching
The mitochondrial network in fibroblasts was stained with an
anti-GRP75 antibody (Abcam, Cambridge, MA) in combination
with the zenon immunolabelling kit (Invitrogen, Carlsbad, CA)
according to manufacturer’s protocol.
The mitochondrial network morphology was investigated using
a fluorescence microscope equipped with an ApoTome and
AxioVision software (all Zeiss, Jena, Germany). By means of
ImageJ 1.42, raw images were binarized, mitochondrion area and
outline were measured and the form factor was calculated (defined
as [Pm
2]/[4pAm]), where Pm is the length of the mitochondrial
outline and Am is the area of the mitochondrion [11]). The form
factor allows quantifying the degree of branching of the
mitochondrial network. Images of at least five randomly selected
cells per individual were analyzed under basal conditions and after
paraquat treatment.
Statistical analysis
The Mann-Whitney U test was applied for comparisons
between mutants and controls. In case of the ATP concentration
and synthesis data, a Mann-Whitney U test was performed to
compare the mutant with the average control values set to 100%
in each run. For evaluation of the impact of stress on cells, the
Wilcoxon matched-pairs signed-ranks test was used to determine
differences before and after treatment. The significance level was
set at 0.05.
Results
We analyzed primary dermal fibroblasts from six PD patients
with homozygous or compound-heterozygous mutations and five
age-matched controls for mitochondrial changes (Table 1).
Respiratory chain function is impaired in Parkin-mutant
fibroblasts
We first determined ATP synthesis rates and cellular ATP
concentrations. These experiments revealed a significant (ATP
synthesis: p = 0.002; ATP level: p = 0.029) reduction of both
parameters in mutants compared to controls (Figure 1A, B).
We next investigated whether the lower ATP synthesis rates and
cellular ATP levels in the patient samples were due to a
dysfunction of respiratory chain enzymes. Kinetic assays per-
formed in mitochondrial preparations showed no significant
differences in complex I activity in patient fibroblasts (median
[interquartile range; IQR]: 72% [66%, 87%], n= 6) compared to
controls (median [IQR]: 100% [80%, 102%], n= 5). Furthermore,
we performed an NADH ferricyanide reductase assay, which
allows to determine the content of functional complex I [26]. This
assay also showed similar levels in mutants (median [IQR]: 87%
[71%, 101%], n = 6) and controls (median [IQR]: 100% [88%,
107%], n= 5). The activities of complexes II+III (median [IQR]:
patients, 134% [85%, 180%], n= 6; controls, 100% [92%, 112%],
n = 5) and IV (median [IQR]: patients, 95% [82%, 108%], n= 6;
controls: 100% [75%, 112%], n = 5) were comparable in Parkin-
mutant fibroblasts and controls.
We then went on to determine the mitochondrial membrane
potential as a central parameter of mitochondrial integrity. Under
basal conditions, the membrane potential was similar in patients
and controls, whereas under paraquat-induced stress, the mutants
showed a significant (p = 0.028) loss (Figure 1C).
Mutant-Parkin alters the cellular oxidative stress level
In order to determine basal levels of oxidative stress in
fibroblasts from Parkin mutants, we applied an OxyBlot. This
technique demonstrated significantly (p = 0.038) higher levels of
oxidized proteins in the Parkin-mutant samples than in controls
(Figure 2A). Under paraquat-induced stress, the difference in
oxidation between mutants and controls increased markedly. Due
to increased variability of the individual results after stress this
result was not significant (Figure 2A). The findings from
densitometric analyses in single individuals were supported by an
OxyBlot performed with pooled control and patient samples under
basal and stress conditions (Figure 2B).
Mitochondrial mass is increased in Parkin-mutant
fibroblasts
Next, we tested mitochondria of our fibroblast samples for
morphological changes since impaired mitochondrial fission
[11,27,28] or the failure to activate mitophagy [18] are well-
established findings in Parkin null mutants.
To compare the degree of mitochondrial network branching in
Parkin mutants and controls, we determined the form factor. This
morphological assessment demonstrated no differences between
mutant and control individuals under basal conditions (Figure 3A–
C). After treatment with paraquat, the degree of branching
decreased by 34% within the controls and by 46% within the
Parkin-mutant samples. This drop was only significant (p = 0.028)
in the latter group (Figure 3A–C).
Finally, to quantify the mitochondrial mass per cell, we
determined the citrate synthase activity in cell lysates. These levels
were significantly (p = 0.004) higher in mutants than in controls
(Figure 3D).
Discussion
In this study we demonstrate that mutations in Parkin cause
abnormal mitochondrial function and morphology in PD patient
fibroblasts.
Oxidative stress is a key element implicated in the pathophys-
iology of PD, as recently further supported by studies on human
skin fibroblasts from PD patients [11,25]. Our results demonstrate
increased oxidative stress levels in Parkin-mutant fibroblasts under
basal conditions. This difference between mutants and controls
became more pronounced when the cells were exposed to
paraquat. In keeping with our findings, a deficiency of the Parkin
interaction partner PINK1 has been reported to cause mitochon-
drial accumulation of calcium in mammalian neurons, resulting in
a mitochondrial calcium overload which then stimulates the
production of reactive oxygen species (ROS) via NADPH oxidase
[29].
Furthermore, there is strong evidence that a deficit in
respiratory chain function is involved in the pathogenesis of PD
[30,31]. In a study on Parkin-mutant fibroblasts, the authors
reported that a decrease in ATP production was linked to complex
I [11]. Here, we determined significantly reduced ATP synthesis
rates and cellular concentrations in patient cells with Parkin
Mutant Parkin in Human Cells
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Figure 1. Mitochondrial function. (A) Basal ATP synthesis rates. The assay demonstrated a significant reduction in ATP production in the Parkin-
mutant patients (median [IQR]: 39% [23%, 55%]) compared to controls (set to 100%). (B) Basal ATP levels. Quantifying the overall cellular ATP
concentration showed significantly lower levels in the mutants (median [IQR]: 69% [58%, 75%]) than in controls (set to 100%). (C) Mitochondrial
membrane potential under basal and oxidative stress conditions. Control (median [IQR]: 100% [94%, 115%]) and patient fibroblasts (median [IQR]:
113% [93%, 128%]) with Parkin mutations show similar membrane potential under basal conditions. When the cells were treated with paraquat
(shaded boxes), no relevant changes were detected in the controls (median [IQR]: 102% [100%, 118%]). In the Parkin mutants, a significant drop of the
membrane potential was observed (median [IQR]: 84% [81%, 103%]). The median, the interquartile range (IQR), the minimum and the maximum value
of 6 (A) or 4 (B) independent experimental runs are plotted. In each experimental run the average ATP level in the controls was set to 100%.
doi:10.1371/journal.pone.0012962.g001
Figure 2. Protein oxidation under basal and stress conditions. Oxidation of proteins in Parkin-mutant fibroblasts and controls was
determined by means of an OxyBlot. (A) When quantifying the protein oxidation in each individual using an antibody against DNP, the Parkin
mutants (median [IQR]: 123% [113%, 136%]) showed significantly higher levels of oxidation than the controls (median [IQR]: 100% [97%, 105%]). After
treatment of the cells with paraquat (shaded boxes), the difference in oxidation between mutants (median [IQR]: 131% [96%, 172%]) and controls
(median [IQR]: 100% [90%, 102%]) increased, but was no longer significant. Equal protein loading was verified with an antibody against b-actin.
Expression ratios of oxidized proteins vs. b-actin were calculated. The median, the interquartile range (IQR), the minimum and the maximum value of
the investigated groups of individuals are given. (B) OxyBlot of pooled protein samples before and after paraquat treatment showing a similar trend
as identified by individual measurements.
doi:10.1371/journal.pone.0012962.g002
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mutations compared to controls. By contrast, we saw no significant
difference in complex I activity between patient samples and
controls. Also the activities of complexes II to IV were not
significantly altered in the Parkin-mutant cells. A possible
explanation for this discrepancy might be a loss of the electron
carrier glutathione or oxidation of ubiquinone due to increased
oxidative stress in the patient cells.
When quantifying the mitochondrial membrane potential as a
central factor of mitochondrial integrity [14], we found no
impairment in the Parkin mutants under basal culturing conditions.
However, exposure to high levels of ROS caused a significant
decline of the membrane potential in these cells. In an earlier
study, the membrane potential was found to be decreased in
Parkin-mutant fibroblasts already under basal conditions and
culturing in glucose depletion medium supplemented with
galactose further worsened the situation [11]. If the mitochondrial
membrane potential data were corrected for mitochondrial mass
per cell, a similar outcome would be expected in our study.
Recently, Parkin has been shown to act downstream of PINK1
in a common pathway which appears to regulate mitochondrial
morphology [27,28,32]. Two studies in human cells also
demonstrated an impact of mutations in Parkin [11] and PINK1
[25] on the shape of the mitochondrial network. Parkin-mutant
cells were found to be more prone to enter fusion as reflected by a
significant increase in mitochondrial branching in the patient
group [11]. By contrast, we detected no significant differences in
the degree of branching between Parkin mutants and controls
under basal conditions but an increase in mitochondrial mass in
the former. In the above-mentioned study [11], fibroblasts were
exposed to rotenone, an inhibitor of the respiratory chain complex
I. This treatment induced mitochondrial fragmentation in Parkin-
mutant and control cells to a comparable extent. Similarly, in our
study, no significant differences in branching between mutants and
controls were detected after exposure to paraquat.
In light of the most recent publications ascribing Parkin a role in
promotion of mitophagy [14,15,16,17] our results can be
interpreted as consequences of the inability of mutant Parkin to
perform its function. In Drosophila, the initiation of mitophagy
depends on ubiquitylation of the fusion factor mfn by parkin.
Following mfn ubiquitylation, dysfunctional mitochondria are
Figure 3. Morphology of the mitochondrial network. (A) Images of the mitochondrial network in control and patient fibroblasts demonstrating
similar degrees of branching under basal culturing conditions. (B) After treatment with paraquat, the network was less branched in patients and
controls. (C) The degree of mitochondrial branching (form factor) was comparable in patients (median [IQR]: 78% [66%, 90%]) and controls (median
[IQR]: 100% [73%, 105%]) under standard cell culturing conditions. When treated with paraquat (shaded boxes), the form factor decreased
significantly in the mutant samples (median [IQR]: 46% [43%, 54%]). By contrast, a drop seen in controls (median [IQR]: 70% [32%, 84%]) was not
significant. (D) Citrate synthase activity in cell lysates. Parkin mutants (median [IQR]: 183% [125%, 232%]) showed significantly higher citrate synthase
activities than controls (median [IQR]: 100% [43%, 101%]), indicative of increased mitochondrial mass per cell in the former. Citrate synthase activity in
cell lysates was normalized for protein concentration. The median, the interquartile range (IQR), the minimum and the maximum value of the
investigated groups of individuals are shown.
doi:10.1371/journal.pone.0012962.g003
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prevented from re-fusion with functional mitochondria [20,21,22].
If this ubiquitylation is impaired in Parkin mutants under stress,
one could imagine that mitochondria with disturbed respiratory
chain function are no longer separated and eliminated from the
general pool but dominate cellular (dys)function. This effect is in
keeping with decreased ATP synthesis rates, elevated oxidized
protein levels, increased mitochondrial mass and the observed
stress-induced loss of mitochondrial membrane potential in the
patient fibroblasts investigated here. Furthermore, one would
expect that due to impaired Mfn1/2 deactivation/degradation,
mitochondria should be less fragmented in Parkin-mutant than in
control cells under stress conditions. Since mitochondrial fusion
and fission are transient events, dynamic techniques to quantify
the degree of mitochondrial branching would be preferable to the
method established so far [11]. Methodological restrictions
together with great inter-individual variations in branching
especially after exposure to mitochondrial stressors render it
impossible to detect subtle morphological differences between
mutants and controls.
In the future, further investigations of the relationship between
changes in mitochondrial dynamics/turnover and cell death will
be necessary to identify potential targets for neuroprotective drugs
redirecting Parkin-mutant cells towards survival. The results from
our study underline that also non-neuronal cells, such as
fibroblasts from patients, allow important insights into the
mechanisms underlying PD and, therefore, will be a useful tool
to pursue this scientific goal.
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